Research Papers:
Catan-ionic hybrid lipidic nano-carriers for enhanced bioavailability and anti-tumor efficacy of chemodrugs
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2080 views | HTML 2700 views | ?
Abstract
Bilin Liu1,*, Dan He1,*, Jianyong Wu1,*, Quan Sun1,*, Mi Zhang1,*, Qunyou Tan2, Yao Li1, Jingqing Zhang1
1Chongqing Research Center for Pharmaceutical Engineering, Chongqing Medical University, Chongqing 400016, China
2Department of Thoracic Surgery, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing 400016, China
*These authors contributed equally to this work
Correspondence to:
Jingqing Zhang, email: [email protected]
Keywords: catan-ionic nano-vesicles, hybrid lipidic nano-carries, effective delivery, bioavailability, antitumor efficacy
Received: October 22, 2016 Accepted: February 22, 2017 Published: March 06, 2017
ABSTRACT
To date there has not been any report on catan-ionic hybrid lipidic nano-carriers, let alone a report on applying them to deliver insoluble anti-tumor drugs. Catan-ionic hybrid lipidic nano-carriers containing curcumin (CUR-C-HLN) inherit the merits of catan-ionic systems, hybrid lipidic systems and nano-structured carriers (the second-generation substitute of solid lipidic nano-systems). Catan-ionic surfactants increased microvesicle stabilization by producing unordered isometric clusters, enhanced absorptive amount as an inhibitor of enzyme and protein, improved tumor accumulation by cellular endocytosis and membranous fusion; hybrid lipids helped to obtain high drug content and low leakage by forming a less-organized matrix arrangement. CUR-C-HLN favorably changed absorptive and pharmacokinetic properties after oral and/or intravenous administrations; improved cell growth inhibition, apoptotic inducing and anti-invasion effects; enhanced antitumor efficiency and reduced cancerous growth. Catan-ionic hybrid lipidic nano-carriers provide an alternative good choice for effective delivery of anticancerous chemodrugs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15942